Biological drugs (sometimes known as "biologics" or "originators") are a type of medication that is derived primarily from biological sources. They are one of the most expensive drugs on the market due to their high cost and difficulty in development. Biosimilar drugs are similar to biologic medicines, but they are not an exact reproduction of the biologic and cannot be labelled a “generic” because of the natural variability involved in their development. The introduction of biosimilars was supposed to shake up the pharmaceutical industry, resulting in reduced prices and greater access to drugs. Market access, on the other hand, has been slower than many expected, with some claiming anti-competitive activities as a barrier to entry and expansion.
- Barriers in Developing Biosimilar Drugs
- Global trends in Biosimilar Drug Market
- Regulatory Constraints
Submit your abstract Today
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Pharmaceutics 2023, Singapore, Abstract Pathology and Patient Safety: The Vital Role of Electronic Medical Record and Pathology Informatics in Error Reduction and Precision Medicine
Consolato M Sergi, University of Ottawa, Canada
Title : Values based practice and the impact on Drug discovery, regulation of the Pharma industry and consent in healthcare”
Ashok Handa, Collaborating Centre for Values Based Practice, United Kingdom